Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has a planned timescale for when romosozumab will be available in the NHS for the treatment of Osteoporosis.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.

NICE published guidance in May 2022 recommending romosozumab for treating severe osteoporosis in people after menopause who are at high risk of fracture. Romosozumab is therefore available for clinicians to prescribe to NHS patients who meet the specified criteria, in line with NICE’s recommendations.